Drugs / SIM0348
Trials 1 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT05718219 | Mar 2023 → Dec 2025 overdue | neoplasm | Jiangsu Simcere Pharmaceutical Co., Ltd. | Active not recruiting | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | SIM0348 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT05718219 ↗ |
| Route | Intravenous | “SIM0348 will be given via IV infusion” NCT05718219 ↗ |